May 16, 2013

$PVCT's PV-10 and $VICL's Allovectin-7

I know this comparison is spurious because apples are not being compared to apples. Nevertheless, it's interesting [at least to me] to consider. Both companies, Provectus and Vical, released information at conferences regarding combination therapies.

In November 2012 Vical released animal data at the 9th International Congress of the Society for Melanoma Research documenting the benefits of combining Allovectin-7 with anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies. The poster is here.

In April 2013 Provectus released data at the American Association for Cancer Research (AACR) Annual Meeting documenting the benefits of combining PV-10 with an anti-CTLA-4 antibody. The poster is here.

Vical's methodology was:

Provectus' low dose (of the anti-CTLA4 antibody) methodology was:

Allovectin's survival graph:

PV-10' low dose (of 9H10) survival graph:
The PV-10 legend is to the left.

No comments:

Post a Comment